150 related articles for article (PubMed ID: 9465500)
21. H2-antagonist maintenance therapy versus Helicobacter pylori eradication in patients with chronic duodenal ulcer disease: a prospective study.
Prach AT; Malek M; Tavakoli M; Hopwood D; Senior BW; Murray FE
Aliment Pharmacol Ther; 1998 Sep; 12(9):873-80. PubMed ID: 9768530
[TBL] [Abstract][Full Text] [Related]
22. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Sonnenberg A; Schwartz JS; Cutler AF; Vakil N; Bloom BS
Arch Intern Med; 1998 Apr; 158(8):852-60. PubMed ID: 9570170
[TBL] [Abstract][Full Text] [Related]
23. Management strategies for duodenal ulcer in India in the helicobacter pylori era: an economic analysis.
Ghoshal UC; Das A
Natl Med J India; 2002; 15(3):140-4. PubMed ID: 12186326
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
O'Brien B; Goeree R; Mohamed AH; Hunt R
Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
[TBL] [Abstract][Full Text] [Related]
25. Costs of duodenal ulcer therapy with antibiotics.
Sonnenberg A; Townsend WF
Arch Intern Med; 1995 May; 155(9):922-8. PubMed ID: 7726700
[TBL] [Abstract][Full Text] [Related]
26. [Modern policy of anti-helicobacter therapy of ulcer disease].
Ryss ES
Klin Med (Mosk); 1998; 76(10):7-11. PubMed ID: 9865008
[No Abstract] [Full Text] [Related]
27. Effect of Helicobacter pylori eradication on the natural history of duodenal ulcer disease.
Goggin N; Rowland M; Imrie C; Walsh D; Clyne M; Drumm B
Arch Dis Child; 1998 Dec; 79(6):502-5. PubMed ID: 10210995
[TBL] [Abstract][Full Text] [Related]
28. Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
Chen SY; Wang JY; Chen J; Zhang XD; Zhang SS
J Gastroenterol Hepatol; 1999 Oct; 14(10):977-83. PubMed ID: 10530493
[TBL] [Abstract][Full Text] [Related]
29. [Impact of the anti-Helicobacter therapy on the life quality of patients with duodenal ulcers].
Guseĭnzade MG
Eksp Klin Gastroenterol; 2005; (5):22-7. PubMed ID: 16518910
[No Abstract] [Full Text] [Related]
30. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
31. [Cost-effectiveness of the eradication of Helicobacter pylori in the treatment of duodenal ulcer].
Domínguez Muñoz JE
An Med Interna; 1998 Oct; 15(10):513-4. PubMed ID: 9844224
[No Abstract] [Full Text] [Related]
32. [Quamatel application in three-drug eradication therapy of duodenal ulcer and gastroduodenal ulcerations associated with helicobacter pylori infection].
Mansurova FKh; Kadyrov DM; Odinaev RI; Ishankulova DM
Klin Med (Mosk); 2000; 78(6):53-6. PubMed ID: 10900873
[TBL] [Abstract][Full Text] [Related]
33. [Eradication of Helicobacter pylori in developing countries].
Rollán A
Rev Med Chil; 1997 Aug; 125(8):939-49. PubMed ID: 9567401
[TBL] [Abstract][Full Text] [Related]
34. [Pharmacoeconomic aspects of the 1-week eradication treatment of duodenal ulcer associated with Helicobacter pylori].
Vasil'ev IuV
Eksp Klin Gastroenterol; 2002; (4):61-4, 133. PubMed ID: 12503280
[TBL] [Abstract][Full Text] [Related]
35. [Recent studies on therapy of peptic ulcers].
Asaka M
Nihon Naika Gakkai Zasshi; 1999 Sep; 88(9):1750-4. PubMed ID: 10581758
[No Abstract] [Full Text] [Related]
36. The cost-effectiveness of competing strategies for the prevention of recurrent peptic ulcer hemorrhage.
Ofman J; Wallace J; Badamgarav E; Chiou CF; Henning J; Laine L
Am J Gastroenterol; 2002 Aug; 97(8):1941-50. PubMed ID: 12190158
[TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori and tolerance to H2-blockers.
Zentilin P; Savarino E; Savarino V
Aliment Pharmacol Ther; 2005 Feb; 21(3):289-90; author reply 290-1. PubMed ID: 15691304
[No Abstract] [Full Text] [Related]
38. Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan.
Ikeda S; Tamamuro T; Hamashima C; Asaka M
Aliment Pharmacol Ther; 2001 Nov; 15(11):1777-85. PubMed ID: 11683692
[TBL] [Abstract][Full Text] [Related]
39. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
Duggan AE; Tolley K; Hawkey CJ; Logan RF
BMJ; 1998 May; 316(7145):1648-54. PubMed ID: 9603748
[TBL] [Abstract][Full Text] [Related]
40. Low dose, short duration therapy for the eradication of Helicobacter pylori in patients with duodenal ulcer.
Iser JH; Buttigieg RJ; Iseli A
Med J Aust; 1994 Feb; 160(4):192-6. PubMed ID: 7906009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
